Rino Vicini1, Dominik Brügger1, Mathias Abegg1, Anke Salmen2, Hilary Michelle Grabe3. 1. Department of Ophthalmology, Inselspital, Bern University Hospital, University of Bern, 3010, Bern, Switzerland. 2. Department of Neurology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland. 3. Department of Ophthalmology, Inselspital, Bern University Hospital, University of Bern, 3010, Bern, Switzerland. hilary.grabe@insel.ch.
Abstract
BACKGROUND: Myelin oligodendrocyte glycoprotein immunoglobulin G associated optic neuritis (MOG-ON) is a recently described entity. Recent studies have shown that MOG-ON has a more severe clinical presentation than classic optic neuritis (ON). OBJECTIVE: This study aimed to define morphological characteristics of MOG-ON, correlate these with clinical characteristics and compare them with multiple sclerosis associated ON (MS-ON) and healthy controls (CTRL). METHODS: In a retrospective study, we included MOG-ON and MS-ON patients seen between 2011 and 2018 at the University Hospital Bern. Data from clinical examination, perimetry, and optical coherence tomography (OCT) were analyzed. RESULTS: A total of 66 eyes of 43 patients were included; 22 MS-ON and 33 CTRL eyes were sex- and age-matched to 11 MOG-ON eyes. We found significantly worse visual acuity at nadir, but better recovery and thinner global peripapillary retinal nerve fiber layer thickness in MOG-ON patients compared to MS-ON patients. Both groups exhibited irregular thinning of the macular ganglion cell layer. Furthermore, the visual acuity and visual field parameters correlated to retinal layer thickness only in MOG-ON eyes. CONCLUSION: In comparison to MS-ON, MOG-ON is associated with more prominent acute vision loss and more pronounced global thinning of the pRNFL. Both entities result in similar final visual acuity and atrophy of the macular ganglion cell layer.
BACKGROUND:Myelin oligodendrocyte glycoprotein immunoglobulin G associated optic neuritis (MOG-ON) is a recently described entity. Recent studies have shown that MOG-ON has a more severe clinical presentation than classic optic neuritis (ON). OBJECTIVE: This study aimed to define morphological characteristics of MOG-ON, correlate these with clinical characteristics and compare them with multiple sclerosis associated ON (MS-ON) and healthy controls (CTRL). METHODS: In a retrospective study, we included MOG-ON and MS-ON patients seen between 2011 and 2018 at the University Hospital Bern. Data from clinical examination, perimetry, and optical coherence tomography (OCT) were analyzed. RESULTS: A total of 66 eyes of 43 patients were included; 22 MS-ON and 33 CTRL eyes were sex- and age-matched to 11 MOG-ON eyes. We found significantly worse visual acuity at nadir, but better recovery and thinner global peripapillary retinal nerve fiber layer thickness in MOG-ON patients compared to MS-ON patients. Both groups exhibited irregular thinning of the macular ganglion cell layer. Furthermore, the visual acuity and visual field parameters correlated to retinal layer thickness only in MOG-ON eyes. CONCLUSION: In comparison to MS-ON, MOG-ON is associated with more prominent acute vision loss and more pronounced global thinning of the pRNFL. Both entities result in similar final visual acuity and atrophy of the macular ganglion cell layer.
Authors: Sarah Chaoying Xu; Randy H Kardon; Jacqueline A Leavitt; Eoin P Flanagan; Sean J Pittock; John J Chen Journal: Neurology Date: 2019-01-23 Impact factor: 9.910
Authors: Elena H Martinez-Lapiscina; Maria Sepulveda; Ruben Torres-Torres; Salut Alba-Arbalat; Sara Llufriu; Yolanda Blanco; Ana M Guerrero-Zamora; Nuria Sola-Valls; Santiago Ortiz-Perez; Pablo Villoslada; Bernardo Sanchez-Dalmau; Albert Saiz Journal: Ther Adv Neurol Disord Date: 2016-08-15 Impact factor: 6.570
Authors: Sven Jarius; Klemens Ruprecht; Ingo Kleiter; Nadja Borisow; Nasrin Asgari; Kalliopi Pitarokoili; Florence Pache; Oliver Stich; Lena-Alexandra Beume; Martin W Hümmert; Marius Ringelstein; Corinna Trebst; Alexander Winkelmann; Alexander Schwarz; Mathias Buttmann; Hanna Zimmermann; Joseph Kuchling; Diego Franciotta; Marco Capobianco; Eberhard Siebert; Carsten Lukas; Mirjam Korporal-Kuhnke; Jürgen Haas; Kai Fechner; Alexander U Brandt; Kathrin Schanda; Orhan Aktas; Friedemann Paul; Markus Reindl; Brigitte Wildemann Journal: J Neuroinflammation Date: 2016-09-27 Impact factor: 8.322
Authors: Joachim Havla; T Kümpfel; R Schinner; M Spadaro; E Schuh; E Meinl; R Hohlfeld; O Outteryck Journal: J Neurol Date: 2016-11-14 Impact factor: 4.849
Authors: John J Chen; Eoin P Flanagan; Jiraporn Jitprapaikulsan; Alfonso Sebastian S López-Chiriboga; James P Fryer; Jacqueline A Leavitt; Brian G Weinshenker; Andrew McKeon; Jan-Mendelt Tillema; Vanda A Lennon; W Oliver Tobin; B Mark Keegan; Claudia F Lucchinetti; Orhun H Kantarci; Collin M McClelland; Michael S Lee; Jeffrey L Bennett; Victoria S Pelak; Yanjun Chen; Gregory VanStavern; Ore-Ofe O Adesina; Eric R Eggenberger; Marie D Acierno; Dean M Wingerchuk; Paul W Brazis; Jessica Sagen; Sean J Pittock Journal: Am J Ophthalmol Date: 2018-07-26 Impact factor: 5.258
Authors: Ilijas Jelcic; James V M Hanson; Sebastian Lukas; Konrad P Weber; Klara Landau; Misha Pless; Markus Reindl; Michael Weller; Roland Martin; Andreas Lutterotti; Sven Schippling Journal: J Neuroophthalmol Date: 2019-03 Impact factor: 3.042
Authors: Elisa Schneider; Hanna Zimmermann; Timm Oberwahrenbrock; Falko Kaufhold; Ella Maria Kadas; Axel Petzold; Frieder Bilger; Nadja Borisow; Sven Jarius; Brigitte Wildemann; Klemens Ruprecht; Alexander U Brandt; Friedemann Paul Journal: PLoS One Date: 2013-06-21 Impact factor: 3.240
Authors: Alexander U Brandt; Hanna G Zimmermann; Norman K Gigengack; Frederike C Oertel; Seyedamirhosein Motamedi; Charlotte Bereuter; Ankelien Duchow; Rebekka Rust; Judith Bellmann-Strobl; Klemens Ruprecht; Tanja Schmitz-Hübsch; Friedemann Paul Journal: Sci Rep Date: 2022-10-20 Impact factor: 4.996